Please ensure Javascript is enabled for purposes of website accessibility

China's CanSino Pushing for Early Authorization for COVID-19 Vaccine

By Eric Volkman – Aug 28, 2020 at 6:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has already been granted permission for use by the Chinese military.

China's CanSino Biologics is currently lobbying regulators abroad to grant its vaccine candidate the equivalent of the U.S. Food and Drug Administration's emergency use authorization (EUA). The company's Senior Vice President for International Business, Pierre Morgon, revealed this in a story published Friday in The Wall Street Journal

Morgon said that his company is talking to regulators in numerous countries, declining to name any save for Pakistan. He also said that discussions are occurring with unnamed nations in Latin America and elsewhere.

A syringe being filled with a vaccine from a vial.

Image source: Getty Images.

According to Morgon, receiving emergency authorization from national regulators "helps to build the safety database and certainly build the confidence in the fact that the vaccine is safe. If, in the meantime, if it is demonstrated as being effective in the Phase 3 trials, then it might be an accelerator for future contracts for vaccine supply."

Although there are a great many COVID-19 vaccine candidates currently in development around the world, none has yet to be approved for widespread use by any major regulator. CanSino's candidate -- currently in a phase 3 clinical trial -- received a Chinese version of an EUA for its candidate to be used by members of that country's military; that authorization does not cover the general population, however.

Only a relatively small number of vaccine candidates are also undergoing late-stage, human clinical trials. Prominent ones include Moderna's (MRNA 3.18%) mRNA-1273 and Pfizer's (PFE 3.06%) BNT162b2 in collaboration with previously low-profile German biotech BioNTech (BNTX 5.64%).

Another, Sputnik V, being developed by Russia's Gamaleya Research Institute, is likewise in late-stage trials. Sputnik V has received an EUA-like "conditional registration certificate" in that country but has yet to be authorized or approved anywhere else.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Pfizer Stock Quote
Pfizer
PFE
$51.78 (3.06%) $1.54
Moderna Stock Quote
Moderna
MRNA
$184.70 (3.18%) $5.70
BioNTech Se Stock Quote
BioNTech Se
BNTX
$171.81 (5.64%) $9.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.